logo
Siren Biotechnology Expands Clinical and Scientific Advisory Board with Key Industry Leaders

Siren Biotechnology Expands Clinical and Scientific Advisory Board with Key Industry Leaders

SAN FRANCISCO, March 05, 2025 (GLOBE NEWSWIRE) -- Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for Cancer, today announced the appointment of three distinguished industry and academic experts to its Clinical and Scientific Advisory Board. The new members bring vast expertise in clinical neuro-oncology and translational cytokine biology and will provide strategic guidance as the company advances its platform of breakthrough AAV immuno-gene therapies.
'We are thrilled to welcome these industry-leading experts to our Clinical and Scientific Advisory Board,' said Dr. Nicole K. Paulk, CEO, Founder, and President of Siren Biotechnology. 'Their deep expertise and insights will be invaluable as we advance AAV immuno-gene therapy to the clinic.'
The new members of the Clinical and Scientific Advisory Board include:
Dr. Samuel C. Blackman, MD, PhD, Co-Founder and former Head of R&D at Day One Biopharmaceuticals – A trailblazer in pediatric oncology drug development, Dr. Blackman is a physician-scientist trained in Pediatric Oncology and Neuro-Oncology and has led the early clinical development of more than 10 novel cancer therapeutics. Most recently, Dr. Blackman played a pivotal role in the development, clinical advancement, and FDA approval of OJEMDA™ (tovorafenib), a breakthrough therapy for pediatric low-grade glioma brain tumors. His extensive experience in early-phase clinical trials and precision medicine approaches has contributed to bringing transformative treatments to young patients in need. Dr. Blackman has held roles at Juno Therapeutics, Merck, Seattle Genetics, GlaxoSmithKline, and Silverback Therapeutics and sits on the Board of Directors for both the Pediatric Brain Tumor Foundation and CureSearch for Children's Cancer.
Dr. Mustafa Khasraw, MD, Professor of Medicine, Neuro-Oncology, Integrative Immunobiology, Pharmacology and Cancer Biology, and Medical Oncologist at Duke University School of Medicine and member of the Duke Cancer Institute – A global expert in Neuro-Oncology, Dr. Khasraw has been at the forefront of clinical research, driving the development of cutting-edge therapeutic strategies for brain cancers. As Deputy Director of the Center for Cancer Immunotherapy at the Duke Cancer Institute, Dr. Khasraw facilitates clinical research and the translation of promising discoveries to the clinic, particularly in the field of immune therapies. His leadership in innovative trial designs has accelerated the translation of promising therapies from bench to bedside, offering new hope to patients with aggressive malignancies. Dr. Khasraw has been Principal Investigator on dozens of brain cancer clinical trials and leads a tumor immuno-biology academic program focused on translational research and clinical trials at the renowned Preston Robert Tisch Brain Tumor Center at Duke University.
Dr. Leonidas Platanias, MD, PhD, Director of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University – An internationally recognized leader in cancer biology and translational medicine, Dr. Platanias has pioneered research on signal transduction pathways in cancer, with a focus on the role of cytokines in cancer and immune response. Dr. Platanias holds the Jesse, Sara, Andrew, Abigail, Benjamin and Elizabeth Lurie Professor of Oncology position in the Departments of Medicine and Biochemistry and Molecular Genetics. He also serves as Associate Vice President for Cancer Programs in Northwestern's Office for Research. Dr. Platanias has published more than 370 papers, and his work has been continuously funded by the National Cancer Institute for almost 30 years. Among his many career honors, Dr. Platanias received the Seymour and Vivian Milstein Award for Excellence in Interferon and Cytokine Research. A member of various scientific societies, he served as President of the International Society of Interferon and Cytokine Research and in other national leadership positions. His groundbreaking contributions have led to advancements in targeted therapies, shaping the development of novel cancer treatments and improved patient outcomes.
The addition of these experts strengthens Siren Biotechnology's commitment to pioneer next-generation AAV gene therapies that harness the power of cytokine immunotherapy to address some of the world's deadliest cancers. Their collective expertise will help advance Siren Biotechnology's innovative platform of AAV immuno-gene therapies, accelerating the development and delivery of potentially transformative treatments to patients who need them most.
About Siren Biotechnology
Headquartered in San Francisco, CA, Siren Biotechnology is sounding the alarm against cancer. We are the pioneers of Universal AAV Immuno-Gene Therapy, which combines the promise of two transformative therapeutic technologies, AAV gene therapy and cytokine immunotherapy, into a single modality which we believe will redefine how we destroy tumor cells and elicit anti-tumor immunity. Our vision is for Universal AAV Immuno-Gene Therapy to become the standard of care for any solid tumor cancer.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Church & Dwight Co., Inc. Issues Voluntary Nationwide Recall of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs Due to Microbial Contamination
Church & Dwight Co., Inc. Issues Voluntary Nationwide Recall of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs Due to Microbial Contamination

Yahoo

time15 hours ago

  • Yahoo

Church & Dwight Co., Inc. Issues Voluntary Nationwide Recall of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs Due to Microbial Contamination

EWING, N.J., June 6, 2025 /PRNewswire/ -- Church & Dwight Co., Inc. is voluntarily recalling all lots within expiry of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs to the consumer level. The products are being recalled due to potential microbial contamination identified as fungi in cotton swab components. Swabs found to contain microbial contamination can potentially present a significant risk to the health and safety of consumers including serious and life-threatening blood infections in users whose nasal mucosa may be compromised due to inflammation and mechanical injuries. The risk is highest (potentially severe or life-threatening) among children and individuals with compromised immune systems or other underlying medical conditions. To date, no serious adverse events associated with the affected product have been reported. The recalled products were distributed nationwide in the United States and in Puerto Rico. Recalled Product Information Zicam® Cold Remedy Nasal Swabs, with UPC 732216301205, all lots: A zinc-free, homeopathic cold remedy swab designed to shorten the duration of the common cold. Zicam® Nasal AllClear Swabs, with UPC 732216301656, all lots: A nasal cleansing swab product (discontinued in December 2024). Orajel™ Baby Teething Swabs, with UPC 310310400002, all lots: Pre-moistened swabs designed to soothe teething discomfort in infants and toddlers. What Consumers Should Do Consumers who have purchased any of the recalled products should stop using the product immediately. Please visit or call its Consumer Relations team at (800) 981-4710 for a full refund. Any additional questions can also be directed to its Consumer Relations team Monday through Friday, 9am – 5pm ET. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax. Complete and submit the report Online: Regular Mail or Fax: Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178. This recall is being conducted with the knowledge of the U.S. Food and Drug Administration. This recall is limited exclusively to Zicam and Orajel swab products. All other Zicam and Orajel products, including Zicam RapidMelts, are not affected by this recall. About Church & Dwight Co., Inc. Church & Dwight Co., Inc. is a leading manufacturer of consumer household and personal care products. For more information, visit Media Contact:Keith View original content to download multimedia: SOURCE Church & Dwight Co. Sign in to access your portfolio

Church & Dwight Co., Inc. Issues Voluntary Nationwide Recall of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs Due to Microbial Contamination
Church & Dwight Co., Inc. Issues Voluntary Nationwide Recall of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs Due to Microbial Contamination

Yahoo

time16 hours ago

  • Yahoo

Church & Dwight Co., Inc. Issues Voluntary Nationwide Recall of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs Due to Microbial Contamination

EWING, N.J., June 6, 2025 /PRNewswire/ -- Church & Dwight Co., Inc. is voluntarily recalling all lots within expiry of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs to the consumer level. The products are being recalled due to potential microbial contamination identified as fungi in cotton swab components. Swabs found to contain microbial contamination can potentially present a significant risk to the health and safety of consumers including serious and life-threatening blood infections in users whose nasal mucosa may be compromised due to inflammation and mechanical injuries. The risk is highest (potentially severe or life-threatening) among children and individuals with compromised immune systems or other underlying medical conditions. To date, no serious adverse events associated with the affected product have been reported. The recalled products were distributed nationwide in the United States and in Puerto Rico. Recalled Product Information Zicam® Cold Remedy Nasal Swabs, with UPC 732216301205, all lots: A zinc-free, homeopathic cold remedy swab designed to shorten the duration of the common cold. Zicam® Nasal AllClear Swabs, with UPC 732216301656, all lots: A nasal cleansing swab product (discontinued in December 2024). Orajel™ Baby Teething Swabs, with UPC 310310400002, all lots: Pre-moistened swabs designed to soothe teething discomfort in infants and toddlers. What Consumers Should Do Consumers who have purchased any of the recalled products should stop using the product immediately. Please visit or call its Consumer Relations team at (800) 981-4710 for a full refund. Any additional questions can also be directed to its Consumer Relations team Monday through Friday, 9am – 5pm ET. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax. Complete and submit the report Online: Regular Mail or Fax: Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178. This recall is being conducted with the knowledge of the U.S. Food and Drug Administration. This recall is limited exclusively to Zicam and Orajel swab products. All other Zicam and Orajel products, including Zicam RapidMelts, are not affected by this recall. About Church & Dwight Co., Inc. Church & Dwight Co., Inc. is a leading manufacturer of consumer household and personal care products. For more information, visit Media Contact:Keith View original content to download multimedia: SOURCE Church & Dwight Co. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Nucor Corporation (NUE): A Bull Case Theory
Nucor Corporation (NUE): A Bull Case Theory

Yahoo

time17 hours ago

  • Yahoo

Nucor Corporation (NUE): A Bull Case Theory

We came across a bullish thesis on Nucor Corporation (NUE) on Business Model Mastery's Substack. In this article, we will summarize the bulls' thesis on NUE. Nucor Corporation (NUE)'s share was trading at $108.94 as of 29th May. NUE's trailing and forward P/E were 19.20 and 14.14 respectively according to Yahoo Finance. A steel rod, bent and contoured to the exact specifications of the company. Nucor stands out as a vertically integrated steel producer operating through three synergistic segments—steel mills, steel products, and raw materials—underpinned by its control of critical inputs, including 3.5 million metric tons of direct reduced iron (DRI) and 18 million tons of recycled scrap annually. This integration enables tight cost control and reliable supply chains. The company's strategic focus on high-value products like insulated panels, overhead doors, and custom racking systems has driven meaningful margin expansion, further bolstered by premium-branded offerings such as ECONIQ™ and AEOS™, which meet growing demand in low-carbon and seismic-resistant construction markets. Nucor's operational flexibility is a core strength, with nearly all production relying on electric arc furnaces (EAFs) that offer rapid scalability and deliver 60–70% lower carbon emissions compared to traditional blast furnaces. Its micro mill strategy and regional footprint enhance both cost efficiency and environmental performance. The company's unique decentralized culture, with just 200 employees at headquarters overseeing over 32,000 teammates, empowers plant-level decision-making and incentivizes performance, driving innovation and responsiveness. This structure supports its aggressive capex-driven growth strategy—$11.8 billion deployed over the past three years, with 63% allocated to capacity expansion and 37% to acquisitions. These investments target fast-growing sectors such as data centers, renewable energy, and automated warehousing, positioning Nucor for long-term structural advantage. The company's integrated model, flexible operations, and disciplined capital deployment collectively support a compelling narrative of margin growth, sustainable production leadership, and strategic evolution in key demand verticals. For a comprehensive analysis of another standout stock covered by the same author, we recommend reading our summary of their of Sanofi (SNY). Since our coverage, the stock is up 4.7%. Nucor Corporation (NUE) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 51 hedge fund portfolios held NUE at the end of the first quarter which was 50 in the previous quarter. While we acknowledge the potential of NUE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store